A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma
第一作者机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China[2]Anyang Tumor Hosp, Anyang, Peoples R China[3]Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Affiliated Canc Hosp, Changsha, Peoples R China[4]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Canc Hosp,Sch Med, Chengdu, Peoples R China[5]Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China[6]Shanxi Canc Hosp, Taiyuan, Peoples R China[7]Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China[8]Xingtai Peoples Hosp, Xingtai, Peoples R China[9]Fujian Canc Hosp, Fuzhou, Peoples R China[10]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[11]Shanghai Henlius Biotech Inc, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Huang Jing,Liu Yun,Wu Tao,et al.A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA:
Huang, Jing,Liu, Yun,Wu, Tao,Liu, Zhen-Yang,Zhou, Jin...&Zhu, Jun.(2023).A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA:
Huang, Jing,et al."A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)